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Background: Exenatide twice daily is a first-in-class glucagon-like peptide receptor agonist 
approved for the treatment of type 2 diabetes. The objective of this analysis was to evaluate the 
safety profile of exenatide twice daily and to compare its profile with that of a pooled comparator 
(placebo and insulin) in patients with type 2 diabetes.
Methods: Data from 19 completed, randomized, controlled clinical trials of exenatide twice 
daily (5 µg and 10 µg) were pooled and analyzed; the pooled data included 5594 intent-to-treat 
patients who were followed for 12–52 weeks. Incidence rates, exposure-adjusted incidence rates, 
and 95% confidence intervals around risk differences between groups were calculated.
Results: Baseline demographics and exposure time were comparable between groups 
(exenatide, N = 3261; pooled comparator, N = 2333; mean exposure time 166–171 days). 
  Transient,   mild-to-moderate nausea was the most frequent adverse event with exenatide (36.9% 
versus 8.3% in the pooled comparator). The incidence of hypoglycemia (minor or major) with 
concomitant sulfonylurea (exenatide 26.5%, pooled comparator 20.7%) was higher than that 
without sulfonylurea (exenatide 3.1%, pooled comparator 2.7%) in all groups. Serious adverse 
events, discontinuations due to serious adverse events, and deaths were reported with similar 
frequency in the exenatide and pooled comparator groups. Composite exposure-adjusted inci-
dence rates were not statistically different between groups for pancreatitis, renal impairment, 
or major adverse cardiac events; there was a difference in incidence rates for benign thyroid 
neoplasm (0.3% versus 0%).
Conclusion: Overall, this analysis, representing over 1500 patient-years of exposure, 
  demonstrated that exenatide twice daily was safe and generally well tolerated in patients with 
type 2 diabetes. The incidence of most adverse events, including serious adverse events, was 
similar in both exenatide-treated and comparator-treated patients. The most distinct differences 
between groups were in gastrointestinal-related adverse events, which is consistent with other 
therapies within the glucagon-like peptide class.
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Background
The glucagon-like peptide (GLP)-1 receptor agonist, exenatide, administered twice 
daily was approved by the US Food and Drug Administration in 2005 for the treat-
ment of type 2 diabetes. In blinded, placebo-controlled and open-label, comparator 
controlled, Phase III clinical trials, exenatide twice daily significantly reduced glycosylated 
hemoglobin (HbA1c, mean −1.0%) in patients with type 2 diabetes who were unable 
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to achieve adequate control with maximally effective doses 
of metformin, sulfonylurea, and/or thiazolidinedione.1 In 
addition to its glycemic effects, exenatide twice daily was 
associated with weight loss (−1 kg to −4 kg) and improve-
ments in several cardiometabolic risk factors over 12 to 
52 weeks in these trials.
As part of ongoing monitoring of the safety of exenatide, 
the goal of the current study was to provide an integrated 
analysis of the safety data from controlled clinical trials 
of exenatide twice daily, including a comparison of the 
exenatide-treated population with a population of pooled 
comparators who were treated with placebo or insulin. The 
data for this retrospective analysis were pooled from all 
completed, randomized, controlled Phase III clinical trials 
conducted by the manufacturer (Amylin Pharmaceuticals, 
Inc. with Eli Lilly and Company), which included 19   trials of 
5594 patients with type 2 diabetes treated for 12 to 52 weeks. 
Primary and secondary efficacy outcomes have been previ-
ously reported for these studies.2–20
Methods
Study participants
Patients from 19 completed, randomized, controlled clinical 
trials, including 13 double-blind superiority trials compar-
ing exenatide with placebo and six open-label noninferiority 
studies comparing exenatide with insulin were included in 
this analysis (Figure 1). For each participating study site, 
a common clinical protocol was approved by an institutional 
review board in accordance with the principles described 
in the Declaration of Helsinki, including all amendments 
through the South African revision of 1996.21 Patients pro-
vided written informed consent before participation.
Patients were between the ages of 18 and 75 years and 
had a baseline HbA1c of #11.0%, a body mass index of 
25–45 kg/m2, and a history of stable body weight (#10% 
variability) for at least 3 months. Patients were excluded from 
these studies if they had used weight loss drugs, had evidence 
of a significant medical condition, or had used specific anti-
glycemic agents, corticosteroids, investigational drugs, drugs 
known to affect gastrointestinal motility, or transplantation 
drugs within the 3 months prior to study screening.
Patients with type 2 diabetes were treated continuously 
for 12–52 weeks with exenatide twice daily (5 µg or 10 µg) 
alone or in combination with metformin, sulfonylurea, and/or 
thiazolidinedione. In patients who received 10 µg exenatide 
twice daily, treatment included a 4-week lead-in period with 
5 µg exenatide twice daily, followed by a dose increase to 
10 µg twice daily for the duration of the trial. Patients in the 
comparator group received insulin (biphasic insulin aspart 
or insulin glargine; open-label trials) or placebo (with or 
without metformin, sulfonylurea, and/or thiazolidinedione 
background therapy; blinded trials).
Statistical analysis
Baseline demographics were summarized for the intent-to-
treat population in each treatment group. The intent-to-treat 
population included all randomized subjects who received 
at least one dose of study medication. Adverse events were 
reported by Preferred Term (using the Medical Dictionary 
for Regulatory Activities (MedDRA v 13.0) and organized 
by organ system class. Adverse events were also analyzed by 
serious adverse events, frequently occurring adverse events, 
study drug-related adverse events, and adverse events of 
interest (eg, gastrointestinal-related adverse events, hypo-
glycemia, thyroid neoplasm, pancreatitis, and cardiovascular 
adverse events). Mild-to-moderate nausea was defined as 
an event of nausea with an intensity of mild or moderate as 
determined by the investigator.
Hypoglycemic episodes were classified as minor 
if the event was associated with symptoms consistent 
with   hypoglycemia and a blood glucose concentration 
of ,54 mg/dL (3.0 mmol/L); events were considered major 
if the event resulted in loss of consciousness, seizure, coma, 
or other change in mental status consistent with neuroglyco-
penia (as judged by the investigator or physician) in which 
symptoms resolved after administration of intramuscular 
glucagon or intravenous glucose, or the event required third-
party assistance because of severe impairment in conscious-
ness or behavior and was accompanied by a blood glucose 
  concentration of ,54 mg/dL (3.0 mmol/L).
For the analysis of major adverse cardiac events (MACE), 
3945 patients from eight randomized placebo-controlled and 
four active comparator-controlled trials were included.2–12,15,22 
A customized MACE definition included terms reflective of 
cardiovascular mortality, stroke, myocardial infarction, acute 
coronary syndrome, and revascularization procedures. The 
risk ratio (RR) for the exposure-adjusted incidence rate and 
its 95% confidence interval (CI) were calculated for MACE. 
It should be noted that patients were excluded from study par-
ticipation if uncontrolled hypertension or a significant history 
of cardiac disease was present at the time of screening, or if 
cardiac disease was present within 1 year of screening.
Renal impairment included all preferred terms defined 
as renal failure- or renal impairment-related, pancreatitis 
included both acute and chronic pancreatitis, and thyroid 
neoplasm included benign neoplasm of thyroid gland and 
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malignant thyroid neoplasm. Additionally,   hypersensitivity 
reactions were assessed relative to positive or negative 
antibody titers to exenatide in a separate analysis of 
2225 patients treated with exenatide twice daily from 
12 controlled trials.23
Incidence rates, exposure-adjusted incidence rate per 
100 patient-years (PY), risk differences (RD) in incidence 
rate or exposure-adjusted incidence rate between groups 
(exenatide incidence rate/exposure-adjusted incidence 
rate – pooled comparator incidence rate/exposure-adjusted 
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Figure 1 Selection of trials for pooled analysis. Of the 61 clinical trials with available data, 19 placebo-controlled or comparator-controlled studies met the criteria for 
inclusion in the pooled analysis.
Abbreviations: BID, twice daily; GAA-I, α-glucosidase inhibitor; InS, insulin; ITT, intent-to-treat; Met, metformin; SFU, sulfonylurea; TZD, thiazolidinedione; w/wout, with/
without.
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incidence rate), and 95% CI around the differences were 
calculated for adverse events.
Results
Patient characteristics and exposure
In this pooled dataset of patients with type 2 diabetes, 5594 
patients were followed for 12–52 weeks, including 3261 
patients receiving exenatide, and 1325 and 1008 patients 
receiving placebo and insulin comparators, respectively. 
Figure 1 lists the demographic and baseline characteristics 
for each treatment group. Demographics were generally 
similar between the exenatide and pooled comparator groups 
and there were no notable differences in baseline HbA1c, 
body mass index, or duration of diabetes. However, in the 
placebo-controlled group, there was a relatively high propor-
tion (26%) of Asian patients because the placebo-controlled 
trials included three studies of Asian populations.10,11,17 
Additionally, the mean exposures to study drug were also 
similar between cohorts, ie, 166 days in the exenatide twice-
daily group and 171 days in the pooled comparator group 
(Figure 2).
Treatment-emergent adverse events  
and discontinuations
Treatment-emergent adverse events were defined as any 
untoward medical event that either occurred or worsened at 
any time after the first administration of study medication, 
through study termination or early termination. Although 
81% of exenatide-  treated patients and 69% of placebo/
comparator-treated patients experienced an adverse event, 
few patients discontinued due to adverse events (8% in the 
exenatide group and 2% in the pooled comparator group). 
Study drug-related adverse events occurred in 48% of patients 
treated with exenatide compared with 16% of patients in the 
pooled comparator group (Table 1). Gastrointestinal-related 
adverse events (51% versus 21%; RD 30; 95% CI: 27.8–32.6) 
were the most frequently reported treatment-emergent 
adverse events associated with exenatide treatment (Tables 2 
and 3). Of the other frequent adverse events, only dizziness 
(5% versus 3%; RD 2; 95% CI: 0.9–3.0) occurred signifi-
cantly more frequently in the exenatide group than in the 
pooled comparator group.
Gastrointestinal-related adverse events were the most 
common reason for study discontinuation: 5.3% of patients 
in the exenatide group and 0.3% of patients in the pooled 
comparator group withdrew due to gastrointestinal-related 
adverse events (Table 1).
Serious adverse events
There was no difference in the rate of serious adverse events 
in either group (4% for both exenatide and pooled comparator 
groups). Study drug-related serious adverse events occurred 
at a frequency of 0.4% in the exenatide group and 0.2% in the 
insulin group (detailed listing in Table 4). Study drug-related 
serious adverse events leading to discontinuation occurred in 
five (0.2%) exenatide-treated patients and two (0.1%) patients 
treated with insulin or placebo (Table 1). There were two 
(,0.1%) deaths in the exenatide group and three (,0.1%) 
deaths in the pooled comparator group (Table 1); however, 
the adverse events that led to patient deaths (ie, atrial fibrilla-
tion and myocardial infarction in exenatide-treated patients, 
stroke in an insulin-treated patient, and myocardial infarction 
in two placebo  treated patients) were not considered by the 
investigator to be related to study drug.
Adverse events of interest
Because of specific safety concerns highlighted by post-
marketing safety surveillance and case reports, several 
adverse events of interest were explored.
Gastrointestinal-related adverse events
Gastrointestinal-related adverse events were reported for 
51% of patients treated with exenatide twice daily and 
in 21% of patients treated with a comparator (RD 30; 
95% CI: 27.8–32.6) and were the most common adverse 
events by organ system class (Table 2). Of the gastroin-
testinal-related adverse events, nausea (37% versus 8%; 
RD 29; 95% CI: 26.6–30.6), vomiting (14% versus 3%; 
RD 11; 95% CI: 9.3–12.0), and diarrhea (11% versus 
5%; RD 5; 95% CI: 3.8–6.6) occurred at a significantly 
greater frequency in the exenatide group than in the 
pooled comparator group (Table 3). The exposure-adjusted 
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Figure 2 Mean treatment exposure. Cumulative duration of exposure (proportion 
of patients within each duration shown) and mean treatment exposure for the 
exenatide (166 days) and pooled comparator (171 days) groups.
Abbreviation: BID, twice daily.
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Table 1 Summary of treatment-emergent adverse events and discontinuations
Patients with treatment-emergent AEs Exenatide BID (N = 3261) Pooled comparator (N = 2333) Risk difference
n (%) n (%) (95% CI)b
With one or more AEs 2653 (81.4) 1613 (69.1) 12.3 (9.9, 14.5)
With study drug-related AEsa 1569 (48.1) 372 (15.9) 32.2 (29.9, 34.4)
With GI-related AEs 1677 (51.4) 495 (21.2) 30.2 (27.8, 32.6)
With serious AEs 119 (3.6) 90 (3.9) −0.3 (−1.2, 0.8)
With serious drug-related AEsa 14 (0.4) 5 (0.2) 0.2 (−0.1, 0.5)
Deaths 2 (,0.1) 3 (,0.1) 0 (−0.2, 0.1)
Discontinued due to AEs 255 (7.8) 43 (1.8) 6.0 (4.9, 7.0)
Discontinued due to drug-related AEsa 207 (6.3) 18 (0.8) 5.5 (4.7, 6.5)
Discontinued due to serious AEs 25 (0.8) 17 (0.7) 0.1 (−0.4, 0.5)
Discontinued due to serious drug-related AEsa 5 (0.2) 2 (0.1) 0.1 (−0.1, 0.2)
Discontinued due to GI-related AEs 173 (5.3) 7 (0.3) 5.0 (4.2, 5.8)
Notes: aDetermined by the investigator to be possibly, probably, or definitely drug-related; brD = Exenatide Ir (%) minus pooled comparator Ir (%).
Abbreviations: AEs, adverse events; BID, twice daily; CI, confidence interval; GI, gastrointestinal.
Table 2 Summary of treatment-emergent adverse events by system organ class
System organ classa Exenatide BID (N = 3261) 
n (%)
Pooled comparator (N = 2333) 
n (%)
Risk difference 
(95% CI)b
Blood and lymphatic system disorders 34 (1.0) 17 (0.7) 0.3 (−0.2, 0.8)
Cardiac disorders 68 (2.1) 53 (2.3) −0.2 (−1.0, 0.6)
Congenital, familial, and genetic disorders 2 (,0.1) 1 (0.0) ,0.1 (−0.1, 0.1)
Ear and labyrinth disorders 49 (1.5) 52 (2.2) −0.7 (−1.5, 0.0)
Endocrine disorders 10 (0.3) 2 (,0.1) 0.2 (−0.0, 0.4)
Eye disorders 90 (2.8) 65 (2.8) 0 (−0.9, 0.8)
Gastrointestinal disorders 1677 (51.4) 495 (21.2) 30.2 (27.8, 32.6)
General disorders and administration site conditions 586 (18.0) 283 (12.1) 5.9 (4.0, 7.7)
Hepatobiliary disorders 24 (0.7) 15 (0.6) 0.1 (−0.3, 0.5)
Immune system disorders 50 (1.5) 29 (1.2) 0.3 (−0.3, 0.9)
Infections and infestations 971 (29.8) 731 (31.3) −1.5 (−4.0, 0.9)
Injury, poisoning, and procedural complications 234 (7.2) 153 (6.6) 0.6 (−0.7, 2.0)
Investigations 231 (7.1) 94 (4.0) 3.1 (1.9, 4.2)
Metabolism and nutrition disorders 1128 (34.6) 719 (30.8) 3.8 (1.3, 6.3)
Musculoskeletal and connective tissue disorders 471 (14.4) 356 (15.3) −0.9 (−2.7, 1.1)
Neoplasms, benign, malignant, and unspecified 36 (1.1) 18 (0.8) 0.3 (−0.2, 0.8)
nervous system disorders 602 (18.5) 332 (14.2) 4.3 (2.3, 6.2)
Pregnancy, puerperium, and perinatal conditions 1 (0.0) 0 (0.0) 0 (−0.0, 0.1)
Psychiatric disorders 153 (4.7) 77 (3.3) 1.4 (0.4, 2.4)
renal and urinary disorders 69 (2.1) 53 (2.3) −0.2 (−0.9, 0.6)
reproductive system and breast disorders 64 (2.0) 34 (1.5) 0.5 (−0.2, 1.2)
respiratory, thoracic, and mediastinal disorders 313 (9.6) 220 (9.4) 0.2 (−1.4, 1.7)
Skin and subcutaneous tissue disorders 260 (8.0) 163 (7.0) 1.0 (−0.4,2.4)
Social circumstances 5 (0.2) 1 (0.0) 0.2 (−0.0, 0.3)
Surgical and medical procedures 86 (2.6) 47 (2.0) 0.6 (−0.2, 1.4)
Vascular disorders 107 (3.3) 78 (3.3) 0 (−1.0, 0.9)
Notes: aEvents listed by system organ class are indicated by number (n) of patients who experienced an adverse event; brD = Exenatide Ir (%) minus pooled comparator Ir (%).
Abbreviations: BID, twice daily; CI, confidence interval.
  incidence rate of gastrointestinal-related adverse events 
was 195 per 100 PY in the exenatide group and 53 per 
100 PY in the pooled comparator group (RD 142; 95% CI: 
131.4–152.3). One serious adverse event each of nausea 
and vomiting were determined to be related to the study 
drug by the investigator at the time of the event (Table 4). 
Gastrointestinal-related adverse events were also among 
the most common adverse events associated with study 
withdrawal in the exenatide group (Table 1).
The incidences of nausea and vomiting decreased 
over time in the exenatide group, regardless of dose. 
The occurrence of nausea decreased from 23.1% during 
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the interval from week 0 to week 4 to 2.2% after week 
28, with a substantial reduction in incidence rate after 
8 weeks of treatment (6.5% during the interval from 
week 8 to week 12,   Figure 3A). Vomiting decreased 
from 6.1% during the interval from week 0 to week 4 to 
1.0% after week 28 (  Figure 3B). There were few recur-
rences of nausea and vomiting events. An analysis of the 
duration of nausea and vomiting demonstrated that the 
nausea and vomiting events associated with exenatide 
treatment twice daily were dose   dependent and that these 
events generally resolved in 1–2 days in most patients   
(Figure 3C and D).
Hypoglycemia
The incidence of hypoglycemia was similar between the groups 
without sulfonylurea use. In a separate analysis of hypoglyce-
mic events by concomitant sulfonylurea use, the incidence of 
hypoglycemia was low in patients who did not use a concomi-
tant sulfonylurea (exenatide 3.1%, pooled comparator 2.7% 
[RD 0.4; 95% CI:−1.1–1.9] vs. with sulfonylurea use, 26.5% 
and 20.7%, respectively [RD 5.8; 95% CI: 3.0–8.6]). Analy-
sis by placebo-controlled or comparator-controlled groups 
and concomitant sulfonylurea showed significant differences 
between the exenatide and placebo subgroups in patients who 
received a sulfonylurea (25% versus 12%; 95% CI: 9.8–16.2) 
and between the exenatide and insulin subgroups who did not 
receive a sulfonylurea (0.9% versus 3.4%; 95% CI: −4.7 to 
−0.2, Figure 4). Thus, of the patients who experienced hypo-
glycemia, 99% of patients in the exenatide group and 93% 
of patients in the pooled comparator group were receiving 
sulfonylurea or insulin at the time of the hypoglycemia event. 
Major hypoglycemia was rare in all treatment groups.
Table 4 Study drug-relateda serious adverse events by preferred term
Preferred termb Study Intensity Outcome Discontinued study due   
to this adverse event
Exenatide BID
Hypertension Heine et al5 Moderate recovered no
Vomiting Heine et al5 Severe recovered no
Injection-site cellulitis nauck et al9 Severe Unknown Yes
nausea nauck et al9 Severe Unknown Yes
Anorexia nauck et al9 Severe Unknown no
Weight loss nauck et al9 Severe Unknown no
Hyperglycemia Davis et al8 Severe recovered Yes
Allergic alveolitis Zinman et al6 Severe recovered no
Gastroesophageal reflux disease DeFronzo et al14 Severe not resolved no
Gastroenteritis DeFronzo et al14 Severe recovered no
Hemorrhoidal hemorrhage DeFronzo et al14 Severe recovered no
Allergic dermatitis Gallwitz et al19 Severe not resolved Yes
Accidental overdose Buse et al20,66 Mild recovered no
Gastritis DeFronzo et al3 Severe recovered Yes
Presyncope Kendall et al4 Severe recovered no
Acute pancreatitis Kadowaki et al17 Moderate recovered Yes
Hypoglycemia Gao et al10 Severe recovered no
Acute myocardial infarction Davies et al13 Severe recovered no
Supraventricular tachycardia Davies et al13 Severe recovered no
Insulin glargine
Ureteric calculus Heine et al5 Severe recovered no
Angiodema Heine et al5 Severe recovered no
Notes: aDetermined by the investigator to be possibly, probably, or definitely related to study drug; bevents listed by preferred term (MedDrA v 13.0 terms) are the individual 
events observed.
Abbreviation: BID, twice daily.
Table 3 Frequent (5%) treatment-emergent adverse events
Preferred terma Exenatide  
BID  
(N = 3261) 
n (%)
Pooled  
comparator  
(N = 2333) 
n (%)
Risk difference   
(95% CI)
nausea 1202 (36.9) 193 (8.3) 28.6 (26.6, 30.6)
Vomiting 442 (13.6) 67 (2.9) 10.7 (9.3, 12.0)
Diarrhea 346 (10.6) 127 (5.4) 5.2 (3.8, 6.6)
Dizziness 173 (5.3) 78 (3.3) 2.0 (0.9, 3.0)
Headache 275 (8.4) 173 (7.4) 1.0 (−0.4, 2.4)
nasopharyngitis 288 (8.8) 219 (9.4) −0.6 (−2.1, 1.0)
Upper respiratory  
tract infection
193 (5.9) 137 (5.9) 0 (−1.2, 1.3)
Notes: Events listed by preferred term (MedDrA v 13.0 terms) are indicated by 
number (n) of patients who experienced an adverse event.
Abbreviations: BID, twice daily; CI, confidence interval.
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renal impairment, thyroid neoplasm,  
and pancreatitis
Renal impairment-related adverse events, including acute renal 
failure, were infrequently reported (1.6 per 100 PY for both 
groups) and there was no significant   difference between groups 
(95% CI: −1.0 to 1.0, Figure 5). Thyroid neoplasms, includ-
ing benign and malignant, were rare. There was a   difference 
in the exposure-adjusted incidence rate of thyroid neoplasms 
between groups, ie, 0.3 per 100 PY (incidence rate , 0.1%) in 
the exenatide group and 0 per 100 PY in the pooled   comparator 
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Cardiovascular-related adverse events
MACE occurred infrequently, with an exposure-adjusted inci-
dence rate of 1.9 per 100 PY with exenatide treatment and 2.3 
per 100 PY with comparators (RR 0.81; 95% CI: 0.43–1.53, 
Figure 5).22 Three cardiovascular events (  hypertension, 
myocardial infarction, and subventricular tachycardia) in two 
patients were designated study drug-related serious adverse 
events by the investigator in the exenatide group.5,13
Antibody formation and immune-related 
and injection site-related events
A separate analysis was performed to characterize antibody 
formation with exenatide and the association between anti-
body formation and injection-site-related adverse events.23 
Antibody titers were characterized from 12   controlled 
studies of patients who received exenatide twice daily for 
up to one year (exenatide, n = 2225; pooled   comparator 
[placebo, insulin, or thiazolidinedione], n = 1591). A patient 
was defined as having treatment-emergent   anti-exenatide 
antibodies if antibodies were present after the first exenatide 
injection following absence of antibodies or missing 
  antibody measurement at baseline, or if the titer increased 
by at least three dilutions from a detectable baseline 
  measurement. The incidence of positive antibody titer was 
35% (31% low titer [#125] and 5% higher titer [625]) 
at endpoint (12–52 weeks). Antibody titers peaked early 
(between weeks 6 and 16) and declined over time (25% of 
patients had positive titers for antibodies at 52 weeks and 
17% had positive titers at 3 years). Overall, there was no 
difference in the incidence of all potentially immune-
related adverse events between treatment groups (7.9% in 
the exenatide group and 7.4% in the pooled comparator 
group). A subset of patients had a slightly greater incidence 
of general disorders and administration site conditions 
associated with a positive antibody titer (2.8%) than with 
a negative titer (0.7%).
Analysis of the incidence rates of injection-site-related 
adverse events in the full analysis (19 studies) indicated that 
these reactions were rare in both groups (data not shown); 
injection site erythema (0.6% versus 0%; RD 0.5; 95% CI: 
0.3–0.8), injection-site pruritus (0.8% versus 0.1%; RD 0.7; 
95% CI: 0.4–1.0), injection-site urticaria (0.1% versus 0%; 
RD 0.1; 95% CI: 0.0–0.2), injection-site rash (0.4% versus 
0%; RD 0.4; 95% CI: 0.2–0.6), and injection-site reaction 
(0.3% versus 0%; RD 0.3; 95% CI: 0.1–0.5) were greater in 
the exenatide group compared with the pooled comparator 
group. The incidence of all other injection-site reactions was 
similar between groups.
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group (RD 0.3; 95% CI: 0.01–0.53,   Figure 5). None of the 
neoplasms were malignant. Acute pancreatitis was rare in the 
patients examined in this   analysis; neither the incidence rate 
(0.1% in both the exenatide and pooled comparator groups 
(95% CI: −0.2 to 0.1) nor the exposure-adjusted incidence rate 
of pancreatitis (exenatide, 0.27 per 100 PY versus pooled com-
parator, 0.18; RD 0.1; 95% CI: −0.28 to 0.45) was   significantly 
different between the groups (Figure 5).
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Discussion
In this analysis of 19 randomized, placebo-controlled and 
active comparator-controlled clinical trials, no specific safety 
signals of concern were identified with the use of exenatide 
twice daily. Overall, exenatide twice daily was safe and gen-
erally well tolerated. The most common treatment-emergent 
adverse events associated with exenatide treatment were 
gastrointestinal, and were mild and transient. The rate of 
serious adverse events and discontinuations due to serious 
adverse events were low overall and occurred at a similar 
rate in both the exenatide and pooled comparator groups. 
The results of long-term extension studies of exenatide twice 
daily (up to 3 years of treatment)24–29 and postmarketing 
surveillance (over 1.6 million PY of exposure since launch) 
support these findings.
The present analysis included only randomized, con-
trolled clinical trials of exenatide twice daily versus placebo 
or insulin, but several uncontrolled, open-label extension 
studies of exenatide twice daily have reported similar 
safety outcomes.24–29 In these open-label extension studies, 
gastrointestinal-related adverse events, particularly nausea 
and vomiting, were frequently reported and were the most 
common adverse events leading to study discontinuation. 
Further, these studies showed a low rate of serious adverse 
events and infrequent occurrence of hypoglycemia in the 
absence of concomitant sulfonylurea use. Of these trials, 
detailed, comparable safety data were reported for the 
3-year endpoint of a large, open-label extension trial of 
527 intent-to-treat patients treated with 10 µg exenatide 
twice daily.26 In this trial, 11% of patients discontinued 
the study due to adverse events; in the present pooled 
analysis, 8% of exenatide patients discontinued due to 
adverse events. Nausea was reported by 59% of patients in 
the extension trial compared with 36.9% of patients in the 
current analysis, and most discontinuations due to adverse 
events were attributed to nausea in both the extension trial 
and our analysis.   Hypoglycemia was reported by 40% and 
30% of patients in the extension trial and current analysis, 
respectively (regardless of concomitant sulfonylurea use), 
but most cases were mild-to-moderate in severity. These 
findings were also reported in a 2009 systematic review by 
Norris et al,1 which also assessed safety results from eight 
of the studies included in the current analysis.
Mild-to-moderate nausea was the most frequently occur-
ring treatment-emergent adverse event in this analysis; 
there was only one case of severe nausea. The GLP-1 
receptor   agonists are generally associated with increased 
gastrointestinal-related adverse events, and it is known that 
  gastrointestinal symptoms are generally more frequent in 
patients with diabetes than in those without diabetes.30–33 
The sensation of nausea with exenatide use is thought to 
be due to slowed gastric emptying, appetite suppression, 
or stimulation of neural GLP-1 receptors. However, with 
continued exenatide use, the frequency and severity of 
  nausea and vomiting   typically decreases over time, and dose 
titration moderates some of these events.1 As in the present 
analysis, studies of long-term use of exenatide twice daily 
have shown that nausea generally subsides with continued 
treatment.24–26,34 Studies of the GLP-  1 receptor agonist, 
liraglutide, have produced similar results with regard to the 
prevalence of gastrointestinal-related adverse events and the 
transient occurrence of nausea.32,33 The ability of antiemet-
ics to mitigate nausea associated with antidiabetic agents is 
unknown given the paucity of data available on this subject 
in the literature. However, a recent analysis indicated that 
predosing with an oral antiemetic before a single 10 µg 
exenatide dose is associated with significant reductions in 
treatment-emergent nausea and vomiting in premedicated 
patients (17% and 7%, respectively) compared with nonpre-
medicated patients (62% and 38%, respectively).35
Although the goal of achieving nearly normal HbA1c 
levels decreases many of the risks of hyperglycemia-related 
complications in diabetes, achieving this goal may be hin-
dered by the occurrence of hypoglycemia.36,37 The incidence 
of hypoglycemia was low, overall, and the rate of these 
events was similar between exenatide-treated patients and 
placebo-treated patients. Most events of hypoglycemia 
occurred with concomitant sulfonylurea use. In the absence 
of concomitant sulfonylurea use, exenatide-treated patients 
experienced rates of hypoglycemia similar to those in patients 
treated with placebo, and lower rates of hypoglycemia than 
patients treated with insulin. Major hypoglycemia was rare 
in all treatment groups.
In addition to an increase in pancreatitis in the general 
population in recent years, which may be due to the greater 
rates of obesity, hyperlipidemia, and obstruction of the com-
mon bile duct by gall stones,38–43 concerns about pancreatitis 
with antihyperglycemic agents have been emphasized by 
postmarketing safety surveillance and case reports.44–48 In 
2007 and 2008, the US Food and Drug Administration issued 
a safety alert and update based on postmarketing surveil-
lance that reported a total of 36 cases of acute pancreatitis 
in patients treated with exenatide.44 However, a definitive 
diagnosis of pancreatitis was not available in all of these 
cases, because many of the patients in the reports did not 
have a computed tomography scan (or other imaging) to 
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confirm the diagnosis; further, most of these patients had 
at least one other risk factor for pancreatitis. In contrast, 
large postmarketing studies found no evidence to support an 
association between exenatide and increased risk of pancrea-
titis.49–52 One study of a large cohort of patients (exenatide 
n = 27,996 and an approximately equal number of matched 
comparators) from a health insurance claims database 
found no association between exenatide and pancreatitis; 
the incidence of acute pancreatitis (0.13%) was comparable 
for initiators of exenatide relative to the comparator group 
(0.12%; RR 1.0; 95% CI: 0.6–1.7).49 Additionally, results 
from an analysis of a national integrated claims database 
showed that patients with type 2 diabetes had a two-fold 
higher risk of pancreatitis and that there was no definite 
association between exenatide use and increased incidence 
of pancreatitis.50 Other antidiabetic therapies have also been 
associated with the development of pancreatitis, but such 
occurrences have been rare.51–53
Obesity and dyslipidemia have been associated with an 
increased risk of developing pancreatitis and are risk factors 
for further morbidity and mortality in patients who have 
pancreatitis.39,41,42 Moreover, patients with type 2 diabetes 
appear to be at increased risk for pancreatitis, as shown by 
two large studies of health care databases.54,55 The first, a 
study of a large US health insurance claims database dem-
onstrated that patients with type 2 diabetes were at 2.8-fold 
greater risk (95% CI: 2.61–3.06) of pancreatitis compared 
with a nondiabetic cohort.54 In the second study of a European 
health database, the risk of developing acute pancreatitis was 
elevated in patients with type 2 diabetes, with an adjusted 
hazard ratio of 1.5 (95% CI: 1.31–1.70).55
Events of exenatide-associated renal impairment or renal 
failure are reported infrequently in published studies.56,57 In the 
current analysis, the exposure-adjusted incidence rate of renal 
impairment was 1.6 per 100 PY in both the exenatide and 
pooled comparator groups. These data are consistent with 
the results of an analysis of six clinical trials58 that found 
no association between exenatide twice daily or placebo in 
renal adverse events and similar changes in kidney function 
between patients in both groups. However, because exenatide 
is primarily cleared via renal mechanisms,59 a labeled warn-
ing remains stating that exenatide twice daily should not be 
used in patients with severe renal impairment (creatinine 
clearance , 30 mL/minute) or end-stage renal disease, 
should be used with caution in patients with renal trans-
plantation, and caution should be exercised when initiating 
or escalating doses of exenatide in patients with moderate 
renal impairment (creatinine clearance 30 to 50 mL/minute). 
Additionally, because exenatide may induce nausea and 
vomiting with transient hypovolemia, treatment may worsen 
renal function.
Thyroid cancers have become a topic of interest with the 
GLP-1 receptor agonists, because sustained GLP-1 agonism 
has been associated with an increased incidence of C-cell 
adenomas and carcinomas in rodents,60 although the clinical 
relevance of the animal data is unknown. In particular, there 
appears to be a species-specific difference in thyroid C-cell 
response to GLP-1 receptor agonists that causes C-cell secre-
tion of calcitonin and hyperplasia in rodents.60 In the present 
analysis, all occurrences of thyroid neoplasm were benign and 
very rare; the exposure-adjusted incidence rate of any thyroid 
neoplasm was 0.3 per 100 PY with exenatide compared with 
no occurrences of thyroid neoplasm with placebo/insulin 
(RD 0.3; 95% CI: 0.01–0.53). Thyroid neoplasm has also 
rarely been reported with liraglutide, and studies monitoring 
calcitonin have indicated similar levels with liraglutide and 
comparators.61–63
Overall, major adverse cardiovascular events were 
uncommon in this analysis. Recently, an association has 
been suggested between use of GLP-1 receptor agonists and 
improvement in cardiovascular risk factors. In an analysis 
of cardiovascular-related events from a large insurance data-
base, exenatide treatment twice daily was associated with a 
lower 10-year risk of cardiovascular-related adverse events 
and hospitalizations than were other antidiabetic treatments.64 
However, data from controlled, adequately powered clinical 
trials with prospectively blinded adjudication of cardiovas-
cular events are needed to evaluate whether exenatide has 
cardioprotective effects; one such trial is underway (EXSCEL 
trial, ClinicalTrials.gov Identifier NCT01144338).
During treatment with GLP-1 receptor agonists, anti-
bodies to treatment may develop in some patients, as has 
been observed with other peptide therapeutics.61,65 Antibody 
formation to therapeutic peptides is common, even when 
the peptide is identical to the endogenous human form. 
Analysis of antibodies showed that 37% of exenatide-
treated patients developed antibodies to exenatide after 
30 weeks of treatment; this rate fell to 17% after 3 years.23 
In   studies of liraglutide, antibodies developed in approxi-
mately 8% of patients who received liraglutide treatment for 
up to 26 weeks.66 Analysis of cross-reactivity in a subset of 
antibody-positive patients showed that treatment-emergent 
antibodies to exenatide did not cross-react with human 
GLP-1 or glucagon. In the LEAD-6 trial of liraglutide, 4.4% 
(five of 113) of antibody-positive samples cross reacted with 
GLP-1. However, because no baseline data were provided 
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for the LEAD-6 patients, it is unknown whether the cross-
reactivity was pre-existing or treatment-emergent.67
It should also be noted that previous studies have indi-
cated that a low antibody titer is not predictive of safety or 
efficacy issues.23 However, results of the subanalysis pre-
sented in this manuscript indicate that there was no differ-
ence between groups in potentially immune-related adverse 
events overall, and only a slight increase in the occurrence 
of some injection-site-related adverse events in patients with 
a positive antibody titer to exenatide.
Strengths and limitations
There are several strengths of this analysis, ie, a large number 
of patients were included in the pooled data set, the trials 
were randomized and controlled with centralized monitor-
ing and laboratory analyses, and the results were derived 
from individual patient data. Limitations were that adverse 
events were not independently adjudicated; the design of 
this analysis was not adequately powered to detect very 
rare adverse events (incidence rate , 0.01%), and the dura-
tion of the trials may not have been long enough to observe 
some adverse events, eg, cancers. Additionally, because the 
pooled comparator included blinded placebo and open-label 
active comparator (insulin) groups, specific adverse events 
associated with the active comparator may have been under-
represented when combined with placebo-related adverse 
events, affecting direct comparisons between the exenatide 
and pooled comparator groups.
Conclusion
This integrated analysis of adverse event data for 5594 patients 
representing over 1500 PY of exenatide twice daily exposure 
provided a comprehensive evaluation of the safety and toler-
ability of exenatide twice daily. The rates of serious adverse 
events were low overall, and incidences were similar in both 
the exenatide and pooled comparator groups.   Discontinuations 
due to adverse events occurred more frequently in the exenatide 
group and were often due to gastrointestinal-related adverse 
events. The greatest differences in incidences between the 
exenatide and comparator groups were in gastrointestinal-
related adverse events, which were also the most frequently 
occurring adverse events with exenatide, a commonality among 
therapies in the GLP-1 receptor agonist class. The occurrence 
of nausea and vomiting may be perceived as treatment-limiting, 
but these events were generally mild in intensity, occurred 
most frequently upon initiation of treatment, and decreased 
over time. In the absence of concomitant sulfonylurea use, 
exenatide-treated patients experienced a low incidence of 
hypoglycemia, with rates of hypoglycemia similar to those 
in patients treated with placebo and lower than in patients 
treated with insulin. Exposure-adjusted adverse event rates 
for pancreatitis, renal-related adverse events, and MACE were 
low and generally similar between groups; thyroid neoplasm 
was also rare with exenatide but the incidence was higher than 
that of the comparator because there were no occurrences of 
thyroid neoplasm with placebo or insulin. Taken together, 
the results of this analysis showed that exenatide twice daily 
was safe and generally well tolerated in patients with type 2 
diabetes mellitus.
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